Regeneron teams up with BioNTech in melanoma (NASDAQ:REGN

published 31.07.2020 09:07

Image of article 'Regeneron teams up with BioNTech in melanoma (NASDAQ:REGN'

Regeneron Pharmaceuticals (NASDAQ:REGN) will collaborate with BioNTech SE (NASDAQ:BNTX) on a clinical trial evaluating the combination of PD-1 inhibitor Libtayo (cemiplimab) and the latter's BNT111 FixVac candidate for the second-line treatment of patients with advanced cutaneous melanoma.

The parties will equally share development costs for the trial and will supply their respective products.

Each will also retain full commercial rights for their respective products.

BNT111, comprised of four melanoma antigens (NY-ESO-1, MAGE-A3, tyrosinase, and TPTE), is the most advanced FixVac candidate in the BNTX's pipeline.

REGN is up and BNTX is up , both on light volume.

by Douglas W. House from

Free awesomeness straight to your inbox!

Sign up now for this free newsletter to receive hand picked content, covering topics like Lifestyle, Business & Technology.

Free Newsletter Sign up now!

..or jump directly to the latest posts!